# A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Study · id `cardio:ct-nct01877915` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01877915](<https://clinicaltrials.gov/study/NCT01877915>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01877915

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Heart failure; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5081 participants.

## Technical summary

Registry record NCT01877915. Randomized; quadruple masking; primary purpose treatment. Start 2013-09-10 (actual); primary completion 2018-04-19 (actual). Results posted on 2019-05-10.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 5081 participants (enrolled count; ClinicalTrials.gov record NCT01877915, source copy `cardio:ctgov-nct01877915-2019-05-10`, retrieved 2026-10-26)
- Started: 2013-09-10 (actual) (ClinicalTrials.gov record NCT01877915, source copy `cardio:ctgov-nct01877915-2019-05-10`, retrieved 2026-10-26)
- Primary completion: 2018-04-19 (actual) (ClinicalTrials.gov record NCT01877915, source copy `cardio:ctgov-nct01877915-2019-05-10`, retrieved 2026-10-26)
- Completion: 2018-04-19 (actual) (ClinicalTrials.gov record NCT01877915, source copy `cardio:ctgov-nct01877915-2019-05-10`, retrieved 2026-10-26)
- Results first posted: 2019-05-10 (ClinicalTrials.gov record NCT01877915, source copy `cardio:ctgov-nct01877915-2019-05-10`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; China; Czechia; Denmark; Estonia; France; Germany; Greece; Hungary; Japan; Latvia; Lithuania; Malaysia; Mexico; Netherlands; Poland; Portugal; Romania; Russia; Slovakia; South Africa; South Korea; Spain; Sweden; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01877915, source copy `cardio:ctgov-nct01877915-2019-05-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01877915-2019-05-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
- Acronym: COMMANDER HF
- Condition: Heart Failure
- Condition: Coronary Artery Disease
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Placebo
- Intervention (Other): Standard of care for heart failure and coronary artery disease
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease (`cardio:pubmed-30146935`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial (`cardio:pubmed-31017637`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial (`cardio:pubmed-31461239`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF (`cardio:pubmed-32171760`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b6c14f42f8fb274ddea5fddca4195a64fc739d400fc812e4189f78ce67f5d574
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
